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OBJECTIVE — Polycystic ovary syndrome (PCOS) is an insulin-resistant state with insulin
resistance being an established therapeutic target; however, measurement of insulin resistance
remains challenging. We aimed to 1) determine serum retinol-binding protein 4 (RBP4) levels
(purported to reﬂect insulin resistance) in women with PCOS and control subjects, 2) examine
the relationship of RBP4 to conventional markers of insulin resistance, and 3) examine RBP4
changes with interventions modulating insulin resistance in overweight women with PCOS.
RESEARCH DESIGN AND METHODS — At baseline, 38 overweight women (BMI
27 kg/m
2) with PCOS and 17 weight-matched control subjects were compared. Women with
PCOS were then randomly assigned to 6 months of a higher-dose oral contraceptive pill (OCP)
(35 g ethinyl estradiol/2 mg cyproterone acetate) or metformin (1 g b.i.d.). Outcome measures
were insulin resistance (total insulin area under the curve) on an oral glucose tolerance test,
RBP4, and metabolic/inﬂammatory markers.
RESULTS — Overweight women with PCOS were more insulin resistant than control sub-
jects, yet RBP4 levels were not different in women with PCOS versus those in control subjects
(35.4  4.3 vs. 28.9  3.1 g/ml, P  0.36). RBP4 correlated with cholesterol and triglycerides
butnotwithinsulinresistance.Metforminimprovedinsulinresistanceby35%,whereastheOCP
worsened insulin resistance by 33%. However, RBP4 increased nonsigniﬁcantly in both groups
(43.7  6.3 vs. 42.6  5.5 g/ml, P  0.92).
CONCLUSIONS — OverweightwomenwithPCOSweremoreinsulinresistantthancontrol
subjects, but this ﬁnding was not reﬂected by RBP4 levels. RBP4 correlated with lipid levels but
not with insulin resistance markers. RBP4 levels did not change when insulin resistance was
reduced by metformin or increased by the OCP. These data suggest that RBP4 is not a useful
marker of insulin resistance in PCOS but may reﬂect other metabolic features of this condition.
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P
olycystic ovary syndrome (PCOS) is
the most common endocrinopathy
in reproductive-age women and af-
fects 7% of this group and up to 30% of
obese women (1). Reproductive abnor-
malities are underpinned by insulin resis-
tance, which has a signiﬁcant etiological
role in PCOS (1). Women with PCOS
have increased insulin resistance com-
pared with that in control subjects
(matched for BMI and body fat distribu-
tion) (1,2), as well as increased incidence
of metabolic syndrome (2), impaired glu-
cose tolerance (IGT), and type 2 diabetes.
However, insulin resistance is not in-
cludedinthediagnosticcriteriaforPCOS.
Challenges include inaccuracy of insulin
assays, lack of clarity on optimal methods
to assess insulin resistance, and ill-
deﬁnedcutoffvaluestodetermineinsulin
resistance (2). A reproducible, accurate
marker of insulin resistance that predicts
outcomes and therapeutic responses
would assist clinical management of PCOS.
Retinol-binding protein 4 (RBP4), an
adipocyte product, is a carrier for vitamin
A in blood. Although the majority of in-
sulin-stimulatedglucoseuptakeoccursin
muscle, in insulin-resistant states, adi-
pose tissue (not skeletal muscle) GLUT4
is downregulated (3). Recent convincing
data in mice suggest a strong causal link
between RBP4 and insulin resistance. Ad-
ipose-speciﬁc GLUT4 knockout mice ex-
hibit insulin resistance with increased
adipose RBP4 (3). Overexpression of
RBP4 in mice induces insulin resistance,
whereasdecreasesinRBP4reduceinsulin
resistance. Furthermore, RBP4 levels can
be normalized by insulin sensitizers and
fenretinide, which reverse insulin resis-
tance in obese rodents. Increased RBP4
impairs insulin signaling in muscle and
increases gluconeogenesis in mouse liver,
suggesting that RBP4 is involved in the
pathogenesis of insulin resistance and is a
marker of insulin resistance in mice.
In contrast, human data are equivo-
cal,withhighadipocyteandplasmaRBP4
levels being reported inconsistently in in-
sulin-resistant states, including obesity,
IGT, type 2 diabetes, and PCOS (3–9).
RelationshipsofRBP4withfeaturesofthe
metabolic syndrome have also been in-
consistently demonstrated (4,6,8). RBP4
has been shown to change with interven-
tions that reduce insulin resistance, in-
cluding weight loss (5,10), exercise (4),
and insulin sensitizers, although results
are variable (8,9). Methodological issues
inthemeasurementofRBP4maycontrib-
ute to inconsistencies, with few studies
using the recommended Western blot
technique (11).
ItisincreasinglyclearthatPCOSisan
insulin-resistant state and insulin resis-
tance per se is an important therapeutic
target. Assessment of insulin resistance is
likely to guide treatment with options in-
cluding the oral contraceptive pill (OCP)
(which can increase insulin resistance) or
metformin (which reduces insulin resis-
tance) (2,12). However, signiﬁcant chal-
lenges remain in the measurement of
insulin resistance (2). Although RBP4
shows promise as a marker of insulin re-
sistance in mice, its role in humans re-
mains unclear. We aimed to clarify the
role of serum RBP4 (using the Western
blot technique) in PCOS by comparing
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andwithoutPCOS.Wealsoexaminedthe
relationship between serum RBP4 levels
andconventionalinsulinresistancemark-
ers,othermetabolicfactors,andadiposity
in women with PCOS. Finally, we exam-
ined the effect of therapeutic interven-
tions that both increase and decrease
insulin resistance in women with PCOS
on serum RBP4 levels.
RESEARCH DESIGN AND
METHODS— This study comprises a
subset of subjects from a larger pharma-
cologic intervention study (12). The sub-
setreportedhereincludes38womenwith
PCOS who were sequentially recruited
and randomly assigned to a treatment
group and who completed the study in-
tervention. Overweight women (BMI
27 kg/m
2) with PCOS (n  38) and
overweightcontrolsubjects(n17)were
recruited using community advertise-
ments. A diagnosis of PCOS was based on
perimenarchal onset of irregular cycles
(21 days or 35 days) and clinical hy-
perandrogenism (hirsutism or acne) or
biochemical hyperandrogenism (eleva-
tion of at least one circulating ovarian an-
drogen level) (1990 National Institutes of
Health criteria). Secondary causes of am-
enorrheaandhyperandrogenismwereex-
cluded with clinical screening and early
follicular 17-hydroxyprogesterone levels.
Type 2 diabetes was excluded by an oral
glucose tolerance test (OGTT) (World
Health Organization criteria). Results of
pregnancy tests were negative before en-
rollment. The Southern Health Research
AdvisoryandEthicsCommitteeapproved
the study, and all participants gave writ-
ten informed consent.
At screening (3 months before base-
line), standard diet and lifestyle advice
was delivered (National Heart Founda-
tion of Australia recommendations), and
medications affecting insulin resistance,
including the OCP, were ceased. At base-
line, women with PCOS were randomly
assigned, on the basis of computer-
generated random numbers, to either
1 g b.i.d. metformin (dose titrated up
over 4 weeks starting at 500 mg b.i.d.)
or a higher-dose OCP (35 g ethinyl
estradiol/2 mg cyproterone acetate) in
an open-label study. The higher-dose
OCP is a commonly prescribed OCP for
women with PCOS in Australia and Eu-
rope. Participants were reviewed by the
same investigator at screening, at base-
line, and at 3 and 6 months after inter-
vention. Data collection was completed
by the research nurse, who blinded to
treatment allocation.
Clinical and biochemical
measurements
Subjects were weighed while lightly
clothed without shoes, BMI was calcu-
lated (weight in kilograms divided by
height in meters squared), and waist and
hip circumferences were measured at the
umbilicus and greater trochanter. The
waist-to-hipratiowascalculatedasthera-
tio of waist circumference to hip circum-
ference. Fasting blood samples were
taken for endocrine and metabolic vari-
ables, and an OGTT was performed at
randomization and at 6 months in the in-
tervention groups.
Venous blood samples were collected
after an overnight fast for assessment of
glucose, insulin, testosterone, sex hor-
mone–binding globulin (SHBG), total
cholesterol,HDLcholesterol,LDLcholes-
terol, triglycerides, high-sensitivity C-re-
active protein (hsCRP) (12), and RBP4.
The free androgen index (FAI) was calcu-
lated as FAI  (testosterone/SHBG) 
100. A 120-min 75-g OGTT was per-
formed,andbloodsamplesweretakenfor
assessmentofglucoseandinsulinat0,60,
120, and 180 min. Total insulin area un-
der the curve (AUC insulin) during the
OGTTwascalculatedgeometricallyusing
the trapezoidal rule. Homeostasis model
assessment (HOMA) was used as a surro-
gate measure of insulin sensitivity and
was calculated as fasting serum insulin
(milliunits per liter)  (fasting plasma
glucose [millimoles per liter]/22.5) as de-
scribedpreviously(12).Becauseoferratic
menstrual cycles, data were not collected
at a speciﬁc cycle stage in women with
PCOS.Controldatawerecollectedduring
the follicular phase.
RBP4
Quantitative Western blotting was per-
formed based on the methods described
by Graham et al. (4,11). In brief, the full-
length recombinant RBP4 protein con-
centration (Cayman Chemical, Ann
Arbor, MI) was determined using the
Bradford method (Bio-Rad, Hercules,
CA). Standard solutions of 25, 50, 100,
and 150 g/ml RBP4 were prepared in a
standard buffer containing 0.1% BSA and
1% Nonidet P-40. Human sera and stan-
dards were then diluted 1:10 into a 1
lithium dodecyl sulfate–PAGE sample
buffer and heated for 5 min at 95°C. In
addition to molecular weight markers, 15
l of diluted standards and samples were
loaded on 16% Tris-glycine precast SDS-
PAGE cassette gels (PAGEgel, San Diego,
CA) and transferred to nitrocellulose
membranes for immunoblotting. Nitro-
cellulose membranes were then blocked
in solution containing 5% nonfat milk in
PBS and Tween 20. Blots were probed
overnight with primary antibody (anti-
RBP4; Sapphire Bioscience, Redfern,
NSW, Australia) diluted 1:500 at 4°C. Af-
ter washing with PBS-Tween 20, blots
wererockedfor1hinsecondaryantibody
(polyclonalgoatanti-rabbitimmunoglob-
ulinhorseradishperoxidase;DAKOCyto-
mation, Kingsgrove, NSW, Australia)
diluted 1:1,000 at room temperature.
Bandsweredetectedbyenzymaticchemi-
luminescence (Millipore, Billerica, MA)
and quantiﬁed using a luminescence im-
aging program (Multigauge, FujiFilm,
Tokyo, Japan).
Assays
Hormone, lipid, and inﬂammatory assays
were completed as described previously
(12).
Statistics
All data are means  SEM and were log-
transformed if not normally distributed.
Results are presented for 55 subjects, 38
with PCOS who were treated with met-
formin (n  19) or the OCP (n  19) and
17 control subjects, except for the data
regarding hsCRP (n  43), for which 12
women with levels 10 mg/l, potentially
attributable to other inﬂammatory pro-
cesses, were excluded. Two-tailed statis-
tical analysis was performed using SPSS
for Windows 14.0 software (SPSS, Chi-
cago, IL) with statistical signiﬁcance set at
an  level of P  0.05. Baseline data were
assessed using one-way ANOVA with
PCOS status as a between-subject factor.
PCOS group was assessed using one-way
ANOVA with intervention as a between-
subject factor and comparisons between
time points were assessed using repeated-
measures ANOVA with intervention as a
between-subject factor. Relationships be-
tween variables were examined using bi-
variate (Pearson) correlations. Change in
variable was deﬁned as the ratio of pre-
treatment value and posttreatment value.
RESULTS— All 17 control subjects
and 38 women with PCOS were screened
and then completed the 3 month run-in.
RBP4 in polycystic ovary syndrome
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PCOS at baseline
Baselineclinical,anthropometric,anden-
docrine characteristics are listed in Table
1. The control and PCOS groups were
similar in age, BMI, and waist-to-hip ra-
tio. Testosterone, FAI, HDL cholesterol,
andtriglycerideswerehigherinthePCOS
group (Table 1). Two markers of insulin
resistance, HOMA and fasting insulin,
were higher in the PCOS group (Table 1).
There was no difference in RBP4 levels
between PCOS and control groups at
baseline (Table 1).
Correlations with RBP4
Pearson correlations showed that RBP4
correlatedwithcholesterol(r0.28,P
0.04) and triglycerides (r  0.30, P 
0.03) at baseline. RBP4 did not correlate
with indexes of insulin resistance, hy-
perandrogenism, or adiposity.
Intervention study
There were no differences in baseline
characteristics for subjects with PCOS
randomlyassignedtometformin(n19)
ortheOCP(n19)(Table2).Therewere
no BMI changes over the study in either
group.
Sex steroids. There was a time-by-
treatment effect for SHBG (P  0.01) and
FAI (P  0.01): SHBG increased with the
OCP and FAI fell, compared with no
changewithmetformin.Atstudycomple-
tion, the OCP group had higher SHBG
and lower FAI (Table 2).
LipidsandhsCRP. Therewasatime-by-
treatment effect for HDL cholesterol (P 
0.01) and triglycerides (P  0.01). HDL
cholesterol decreased with metformin
and did not change with OCP. Triglycer-
ides increased with the OCP, but did not
change with metformin. LDL cholesterol
decreasedwiththeOCP,withnotime-by-
treatment effect. At completion, the OCP
group demonstrated higher HDL choles-
terol (P  0.01). There was a time-by-
treatment effect for hsCRP (P  0.03)
withanonsigniﬁcantreductionwithmet-
formin and a nonsigniﬁcant increase with
OCP.
Insulinresistance. Therewasatime-by-
treatment effect for AUC insulin (P 
0.01) with a 33% increase in AUC insulin
with the OCP and a 35% decrease with
metformin(Fig.1A),andthegroupswere
signiﬁcantly different after treatment.
RBP4. Despite decreased insulin resis-
tancewithmetforminandincreasedinsu-
lin resistance with the OCP, RBP4 levels
didnotchangeineithergroup.Therewas
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ter intervention (Fig. 1B).
Correlations with change in RBP4.
Within the two groups, a change in RBP4
did not correlate with changes in insulin
resistance, metabolic factors, or indexes
of adiposity.
CONCLUSIONS — Recent compre-
hensive studies in mice provide convinc-
ing evidence of a link between insulin
resistance and RBP4 (3). However, hu-
mandatahavebeenlessconsistent.PCOS
is a known insulin-resistant state, and in
the current human PCOS study, we have
demonstrated on the basis of HOMA that
womenwithPCOSaremoreinsulinresis-
tant than overweight control subjects but
do not have different RBP4 levels. Fur-
thermore, in PCOS, RBP4 levels did not
correlate with other insulin resistance
markers and did not change with inter-
ventions including metformin (which re-
duced insulin resistance) and the OCP
(which increased insulin resistance).
These data suggest that RBP4 is not a use-
ful marker of insulin resistance in PCOS.
To date, human studies have failed to
clarify the role of RBP4 as a marker of
insulin resistance. RBP4 has been re-
ported as high and correlated inversely
withinsulinsensitivity(withahyperinsu-
linemic-euglycemic clamp) in subjects
with IGT and type 2 diabetes and nono-
bese relatives of subjects with diabetes
(4). These populations mostly had abnor-
mal glucose metabolism (AGM) rather
than isolated insulin resistance and were
predominately male. In one comparison
of obese subjects with and without type 2
diabetes, the relationship between RBP4
and insulin resistance was not indepen-
dent of BMI (4). Thus, the isolated contri-
bution of insulin resistance cannot be
determined. Recently, RBP4 correlations
with insulin resistance have been incon-
sistent. Cho et al. (6) reported high
plasma RBP4 levels in weight-matched
humans with IGT and type 2 diabetes;
however, RBP4 did not correlate with in-
sulin resistance. Morbidly obese patients
had high RBP4 levels compared with lean
control subjects but notably also had
AGM with elevated fasting glucose (5).
RBP4 was not elevated in obese post-
menopausal women without type 2 dia-
betes (8) and did not correlate with
insulin resistance.
Obese women with PCOS present
Table 1—Characteristics at baseline of control subjects versus women with PCOS
Baseline characteristic Control PCOS P value
n 17 38
Age (years) 33.2  1.9 34.1  1.2 0.68
BMI (kg/m²) 36.9  1.4 36.8  1.2 0.98
Weight (kg) 97.6  4.3 99.6  3.5 0.73
Waist circumference (cm) 108.7  3.4 108.9  2.6 0.94
Waist-to-hip ratio 0.85  0.01 0.86  0.01 0.47
hsCRP (mg/l) 3.3  0.51 4.1  0.5 0.36
Testosterone (nmol/l) 1.3  0.2 2.2  0.1 0.01
SHBG (nmol/l) 40.4  4.5 31.9  2.5 0.08
FAI 4.5  0.9 10.3  1.6 0.01
Fasting glucose (mmol/l) 4.5  0.1 4.5  0.1 0.88
Fasting insulin (mU/l) 10.3  1.2 21.2  3 0.01
Cholesterol (mmol/l) 4.8  0.2 5.2  0.2 0.1
HDL cholesterol (mmol/l) 1  0 1.3  0.1 0.01
LDL cholesterol (mmol/l) 3.3  0.2 3.3  0.2 0.9
Triglycerides (mmol/l) 0.9  0.1 1.4  0.1 0.01
HOMA 2.1  0.3 4.5  0.7 0.02
RBP4 (g/ml) 28.9  3.1 35.4  4.3 0.36
Data are means  SEM unless otherwise indicated.
Figure 1—Changes in RBP4 (A) and AUC insulin on an OGTT (B) after metformin ( )o rt h e
OCP ( ) for 6 months. Data are means  SEM. Data were assessed using repeated-measures
ANOVA with time as the within-subject factor and intervention as the between-subject factor.
*Time-by-interventioneffect(P0.01)withadecreaseinAUCinsulinformetformin(P0.03)
and increase for OCP (P 0.01)
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the onset of AGM and have extrinsic obe-
sity-related insulin resistance in addition
to intrinsic PCOS-related insulin resis-
tance. They are more insulin resistant
than weight-matched control subjects
(2). Hence, women with PCOS provide a
useful model to investigate whether RBP4
reﬂects insulin resistance independent of
AGM. Women whose PCOS is diagnosed
on the basis of the National Institutes of
Health criteria demonstrate more severe
insulin resistance (13,14). Although our
resultsdemonstrateadifferenceininsulin
resistance (HOMA) between overweight
women with PCOS and control subjects,
RBP4 did not differ between groups. Sim-
ilarly, Hahn et al. (15) did not detect a
difference in RBP4 between lean women
with PCOS and lean control subjects.
However, in a study in 10 obese, insulin-
resistant women with PCOS (7), higher
RBP4 levels were seen than those in
weight-matched control subjects. Of
note, the enzyme-linked immunosorbent
assay (ELISA) method was used rather
thantheWesternblot.Tanetal.(7)noted
that women with PCOS had a signiﬁ-
cantlyhighermeanfastingglucose(upper
limit of normal range) than control
women and that RBP4 correlated with
glucose but not with HOMA or insulin
levels,suggestingthatRBP4reﬂectsAGM,
not insulin resistance. This result is con-
sistent with those in the current study
with no difference in RBP4 in a popula-
tion with insulin resistance but without
AGM. Although PCOS is an insulin-
resistant state, PCOS per se and insulin
resistance do not seem to be related to
high RBP4 levels.
We did not demonstrate a correlation
between serum RBP4 levels and markers
of insulin resistance in overweight
women with PCOS at baseline, conﬁrm-
ing previous observational PCOS studies
(7,15). Other than that of Graham et al.
(4), most studies in weight-matched dia-
betic and obese subjects have not demon-
strated a relationship with RBP4 and
insulin resistance (5,6,8,10). We showed
a correlation with RBP4 and triglycerides,
which has been noted previously (4,15).
RBP4correlateswithadipositymarkersor
AGM relatively consistently across other
studies;however,wedidnotdemonstrate
these correlations in relatively homoge-
neous overweight women with PCOS
who had predominately normal glucose
tolerance.
In the current study, despite demon-
strating decreased insulin resistance after
6 months of metformin and increased in-
sulin resistance with the OCP in over-
weight women with PCOS, we were
unable to show any relationship between
change in insulin resistance and RBP4.
RBP4 has been shown to change with in-
terventions that reduce insulin resistance
in other insulin-resistant populations al-
though results are variable. RBP4 (ELISA)
decreased with 13% weight loss after lap-
banding, although there was no decrease
in insulin resistance (5). Similarly, no re-
lationship was seen between RBP4 and
decreased insulin resistance during
weight reduction in obese women (10).
Conversely, 5% weight loss did not
change RBP4, despite a decrease in insu-
lin resistance (8). In 60 subjects, exercise
training improved insulin resistance (eu-
glycemicclamp).Asigniﬁcantdecreasein
RBP4 was detected with post hoc analysis
in the most insulin-resistant subjects, in
whom exercise improved insulin resis-
tance markedly (4). RBP4 levels are nor-
malized in mice treated with the insulin
sensitizer rosiglitazone. Treatment of hu-
man subjects who have IGT with the in-
sulin sensitizer pioglitazone resulted in a
paradoxical increase in RBP4 expression
in adipose tissue, despite a decrease in
insulin resistance. Serum RBP4 was un-
changed with pioglitazone and met-
formin, consistent with results in the
current study (9).
FAI is preferable to testosterone as a
marker of androgen excess in women
with PCOS. In the current study, FAI and
testosterone decreased with the OCP,
with no change with metformin, consis-
tent with results in a Cochrane review
(16). Two recent studies noted that tes-
tosterone and FAI decreased with met-
formin, yet both studies noted a decrease
in BMI (17,18). The lack of changes in
androgens with metformin in the current
study may be related to stable BMI or to
sample size.
The dyslipidemia of PCOS has both
similarities with type 2 diabetes (elevated
triglycerides) and differences (HDL cho-
lesterol is not low), as noted here and in a
large study by Legro et al. (19). In the
current study, HDL cholesterol decreased
with metformin and was unchanged with
the OCP, whereas triglycerides increased
with the OCP. Other studies have shown
similar ﬁndings (12,17), yet a Cochrane
review in PCOS (16) showed no changes
in HDL cholesterol with metformin. This
result contrasts with ﬁndings in type 2
diabetes, in which HDL cholesterol in-
creases with metformin (20). These ob-
servations warrant further exploration
but add to mounting evidence that PCOS
is distinct from diabetes from both a re-
productive and metabolic perspective.
Inconsistentresultsmaybeattributed
to inaccuracies of the commercial ELISA
RBP4 assays (11) and to variations in as-
sessment of insulin resistance. Only stud-
ies using hyperinsulinemic-euglycemic
clamps showed a correlation with RBP4
(4).WesternblottingyieldsRBP4concen-
trations with a greater dynamic range
than the ELISA (11). The ELISA may un-
derestimate the differences in RBP4 be-
tween insulin-sensitive and insulin-
resistant subjects. Enzyme immunoassay
has been shown to undervalue RBP4 con-
centrations, possibly because of assay sat-
uration in insulin resistance. Some
commercial ELISAs use urinary RBP4 as
the protein standard rather than the full-
length form found in serum, leading to
greater immunoreactivity. These issues
have led to the recommendation that
quantitative Western blotting, standard-
ized to full-length RBP4 protein, should
be used to measure RBP4 in insulin-
resistant states (11).
Insulin-resistant mice have high
RBP4 in adipose tissue and serum, and
these elevations can be normalized by in-
sulin sensitizers (3). Increasing RBP4 in
mice induces insulin resistance, whereas
decreasing RBP4 enhances insulin sensi-
tivity. However, RBP4 was one of ﬁve
messenger RNAs encoding proteins iden-
tiﬁed in adipose tissue when DNA array
analysis was performed on insulin-
resistant, adipose-speciﬁc GLUT4 knock-
out mice (3). Work with the remaining
identiﬁedproteinsmayelucidatetherela-
tionship between the downregulation of
adipose-speciﬁc GLUT4 in humans and
insulin resistance.
Strengths of our study include both a
baseline and intervention phase with
higher insulin resistance in PCOS at base-
line, supported by intervention data with
differential effects of medical therapy on
insulin resistance without a change in
RBP4.WehavealsousedtheWesternblot
technique to determine RBP4. The study
was limited by a relatively small sample
size. Although the accurate measurement
of insulin resistance is challenging, the
HOMA score and AUC insulin during an
OGTT appear to be comparable to those
with the hyperinsulinemic-euglycemic
clamp technique in PCOS (21,22); how-
ever, clamp studies may have been more
accurate.
Although women with PCOS are
Hutchison and Associates
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control subjects, this fact was not re-
ﬂected by RBP4 levels. RBP4 did not cor-
relate with other markers of insulin
resistance in overweight women with and
without PCOS. In addition, RBP4 did not
change with changes in insulin resistance
from therapeutic interventions including
metformin(reducedinsulinresistance)or
the OCP (increased insulin resistance).
RBP4 did correlate with lipid levels, sug-
gestingthatRBP4isnotausefulmarkerof
insulin resistance but may reﬂect meta-
bolic abnormalities in PCOS.
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